Core Points - Veeva Systems will host its 2025 Investor Day virtually on October 16, 2025, from 1:30 p.m. PT to approximately 3:30 p.m. PT [1] - The event will be broadcast live on the company's investor relations website, with an archived webcast available afterward [1] Company Overview - Veeva Systems provides industry cloud solutions for life sciences, including software, data, and business consulting [2] - The company serves over 1,500 customers, including major pharmaceutical companies and emerging biotechs [2] - As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, and shareholders [2] Disclosure Practices - Veeva utilizes its investor relations website to disclose material non-public information and announce upcoming investor conferences [3] - Stakeholders are encouraged to monitor the investor relations website along with press releases and SEC filings for updates [3]

Core Insights - Bristol Myers Squibb (BMS) has committed to using Veeva Vault CRM to enhance customer engagement and decision-making in healthcare [1][2][3] Company Developments - Veeva Systems announced the partnership with BMS, highlighting the integration of AI into the customer journey to improve healthcare practitioner engagement [2][3] - The first Veeva AI agents for Vault CRM, including Pre-call Agent, Content Agent, Free Text Agent, and Voice Agent, are expected to be available in December 2025 [3] Industry Impact - The collaboration aims to transform how healthcare practitioners access information about innovative medicines, thereby supporting BMS's mission to deliver life-changing treatments to patients [2][3] - Veeva Systems serves over 1,500 customers in the life sciences sector, indicating a strong market presence and commitment to innovation [4]

Core Viewpoint - Dividend cuts can present investment opportunities, as the negative news is often already priced in, leading to potential undervaluation of assets [3][7]. Group 1: Market Reactions to Dividend Cuts - Wall Street analysts and individual investors often react negatively to dividend cuts, leading to knee-jerk selling of affected funds [2][3]. - BlackRock Health Sciences Term Trust (BMEZ) experienced a dividend cut, prompting some investors to sell, but this creates opportunities for contrarian investors [3][5]. Group 2: Closed-End Funds (CEFs) Dynamics - CEFs operate differently from ETFs or mutual funds, raising a fixed pool of capital at launch, which can lead to inefficiencies in trading [4]. - When investors sell CEF shares without considering underlying assets, discounts can widen, creating buying opportunities for savvy investors [4][7]. Group 3: BMEZ Fund Characteristics - BMEZ currently yields 9.2% and trades at an 11% discount to its net asset value (NAV), indicating a potential buying opportunity [7][12]. - The fund's portfolio includes biotech and medical device companies that may benefit from a favorable regulatory environment [6][8]. Group 4: Key Holdings and Performance - Alnylam (ALNY), a top holding in BMEZ, focuses on innovative RNA interference therapies and has seen significant stock gains under previous administration policies [8][9]. - Veeva Systems (VEEV), another key holding, has also performed well historically, benefiting from a favorable mergers and acquisitions environment [9][10]. - Dexcom (DXCM), the third largest holding, produces continuous glucose monitors and has experienced substantial stock growth [11]. Group 5: Future Outlook - The current administration's policies may support the healthcare sector, particularly for companies in BMEZ's portfolio, which could lead to further growth [12].

Group 1 - Alnylam Pharmaceuticals Inc is focused on developing therapies based on RNA interference technology, which has shown promise in treating rare genetic diseases [1] - DexCom Inc specializes in continuous glucose monitoring systems for diabetes management, indicating a growing demand for innovative health technology solutions [1] - Veeva Systems Inc Class A provides cloud-based software solutions for the global life sciences industry, highlighting the increasing reliance on digital transformation in healthcare [1] Group 2 - BlackRock Health Sciences Trust II is an investment vehicle that targets companies in the health sciences sector, reflecting investor interest in healthcare as a resilient investment area [1]

Core Insights - TimesSquare Capital Management's "U.S. Focus Growth Strategy" reported strong performance in Q2 2025, with equities achieving double-digit returns as global economic activity expanded [1] - Growth indexes outperformed value counterparts, with U.S. small and mid-cap growth indexes showing better returns from stocks with high valuations, negative earnings, or low returns on equity [1] - The strategy returned 11.79% (gross) and 11.56% (net), compared to an 18.20% return for the Russell Midcap Growth Index [1] Company Focus: Veeva Systems Inc. (NYSE:VEEV) - Veeva Systems Inc. reported a one-month return of -0.14% and a 52-week gain of 24.85%, with a market capitalization of $45.009 billion as of September 10, 2025 [2] - The strategy received a 24% boost from Veeva Systems, which surpassed revenue and earnings expectations, achieving total revenue of $789 million [3][4] - Veeva's commercial subscription revenue growth accelerated, driven by its Crossix platform, and new AI-embedded features were announced for its Vault suite [3] Hedge Fund Interest - Veeva Systems was held by 61 hedge fund portfolios at the end of Q2 2025, an increase from 55 in the previous quarter [4] - Despite strong results, the company is not among the 30 most popular stocks among hedge funds, with some analysts suggesting other AI stocks may offer greater upside potential [4]

Core Insights - Gilead Sciences has committed to using Veeva Vault CRM, enhancing their long-standing partnership with Veeva Systems [1][2][7] - Veeva Vault CRM is designed to improve commercial execution through advanced AI capabilities, including pre-call planning and voice control [2][3] Company Overview - Veeva Systems provides cloud-based software and services tailored for the life sciences industry, serving over 1,500 customers, including major biopharmaceutical companies [3] - Gilead Sciences is a biopharmaceutical company focused on innovative medicines for life-threatening diseases, operating in over 35 countries [4]

Core Viewpoint - Veeva (NYSE: VEEV) is experiencing accelerated revenue growth, leading to a reiterated "buy" rating with a price target of $322 per share [1]. Company Overview - Veeva is positioned in the market as a growth-driven company focusing on sustainable investment strategies [1]. Investment Strategy - The investment strategy emphasizes maximizing shareholder equity by targeting companies that meet growth-oriented goals [1]. Analyst Background - The analyst has extensive experience in high-growth supply-chain start-ups and has worked with venture capital firms, enhancing user acquisition and maximizing returns during the pandemic [1]. Financial Literacy - The analyst aims to democratize financial literacy, making complex macroeconomic concepts more accessible and empowering for investors [1].

Group 1 - The analyst has previously given a buy rating to Veeva Systems (NYSE: VEEV) based on confidence in its long-term growth outlook and execution capabilities [1] - Recent results have strengthened the analyst's conviction regarding Veeva Systems' performance [1] - The investment approach focuses on identifying undervalued companies with long-term growth potential, blending value investing principles with a long-term growth focus [1]

Core Insights - The new CFO, Brian Van Wagener, reflects on his first year in the role, describing it as a journey filled with challenges and learning experiences [1][2] - The CFO's background is primarily in operations, having previously served as Chief of Staff and in sales operations before transitioning to the CFO position [2] Group 1 - The CFO acknowledges some initial difficulties but emphasizes a positive overall experience in the first year [1] - The transition from operations to finance is highlighted as a unique aspect of the CFO's background, which may influence the company's strategic direction [2]

Summary of Veeva Systems (VEEV) 2025 Conference Call Company Overview - **Company**: Veeva Systems (VEEV) - **Event**: 2025 Conference at Citi Tech Conference - **Date**: September 04, 2025 Key Points Company Transformation and Strategy - The company is undergoing a transformation and inflection point, focusing on entering new markets and horizontal software, which is seen as the "third act" of Veeva [4][59] - Significant investment in AI is expected to drive change within Veeva and the industry [5] Financial Performance - Q2 billings were subdued due to timing factors, not indicative of long-term business trajectory; revenue and subscription revenue are better indicators of momentum [6][7] - The company raised guidance for the full year across all lines, including revenue, billings, and cash flow, reflecting confidence in the business [7][8] CRM Migration and Competitive Position - Veeva has transitioned from Salesforce to its own Vault CRM, with nine commitments from top 20 pharma companies, indicating strong market traction [9][12] - The migration is expected to yield significant gross margin benefits, with an estimated $80 million in royalty payments to Salesforce being eliminated over time [28] - The company is confident in its ability to win back customers from Salesforce if implementations do not go well [16] Crossix Business Performance - Crossix is performing well, with over $200 million in ARR, driven by investments in product development and a dedicated field team [30][31] - The Audiences business within Crossix is experiencing strong growth, supported by healthy customer marketing budgets [33] Partnership with IQVIA - A new partnership with IQVIA has been established, resolving a long-standing legal dispute and creating opportunities for collaboration in data and clinical markets [35][41] - The partnership is expected to reduce friction for customers and enhance the value proposition of both companies' offerings [41] R&D and Product Development - Veeva has achieved high penetration in the eTMF product, with 20 of the top 20 pharma companies standardized on it, providing a strong foundation for further innovation [52] - The company is focused on expanding its suite of applications in R&D, with a low current penetration rate of around 15% [55] Horizontal Software Market - Veeva is exploring opportunities in the horizontal enterprise application market, which is seen as a long-term growth strategy [59][60] - The company aims to leverage its software capabilities to innovate in this space, emphasizing a commitment to customer success [60] Market Environment and Customer Sentiment - Despite uncertainties in the industry, life sciences companies are continuing to modernize their systems and execute their projects effectively [62][63] - The company remains optimistic about its growth trajectory, supported by a diverse portfolio of products and a strong execution strategy [66][68] Future Outlook - Veeva's long-term targets imply low teens growth, supported by a broad-based portfolio approach and multiple products entering steep adoption phases [65][66] - The company is focused on leveraging AI to enhance quality and speed, rather than solely for margin accretion [70] Additional Insights - The transition to Vault CRM is expected to enhance product excellence and customer success, which are core to Veeva's strategy [27][28] - The company is committed to competing in the data market while maintaining a respectful relationship with IQVIA [45][49]